文献速递间质性肺疾病

吸入色甘酸钠新制剂PA101治疗特发性肺纤维化与慢性咳嗽的随机对照2期试验

A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial.
PubMed 文献 · Lancet Respir Med · 2017-09-08

这项随机、双盲、安慰剂对照、概念验证2期试验在特发性肺纤维化(IPF)伴慢性咳嗽患者中评估吸入PA101(40 mg,每日三次,共2周)的疗效与安全性,并在慢性特发性咳嗽(CIC)患者中平行探索其镇咳机制。

要点

  • PA101在慢性特发性咳嗽患者中未观察到镇咳获益。
  • PA101耐受性良好,不良事件发生率与安慰剂相似,多为轻度。

核心结论

  • 吸入PA101可能成为IPF患者慢性咳嗽的治疗选择,值得进一步研究。
  • IPF中咳嗽的机制可能是疾病特异性的。

研究设计与样本

  • 随机、双盲、安慰剂对照、概念验证2期试验,纳入IPF伴慢性咳嗽患者24例,随机1:1接受PA101 40 mg或安慰剂每日三次吸入2周,洗脱2周后交叉。
  • 平行开展相似设计的CIC研究,纳入28例,27例接受治疗。

主要发现

  • IPF患者PA101组日间咳嗽频率从基线均值55(SD 55)次/小时降至第14天39(29)次/小时,安慰剂组从51(37)次/小时至52(40)次/小时。
  • 两队列中PA101耐受性良好,不良事件发生率与安慰剂相似,多为轻度,未报告严重不良事件或重度不良事件。

关键数值与推荐

  • IPF患者主要疗效终点为日间客观咳嗽频率较基线的变化(24小时声学记录,Leicester Cough Monitor)。
  • PA101剂量为40 mg,每日三次经口吸入,疗程2周。

临床怎么用

  • 对于IPF伴慢性咳嗽患者,吸入PA101可能作为潜在治疗选择,但需进一步研究验证。
  • CIC患者不应预期从PA101中获得镇咳获益。

局限性

  • 研究为小样本概念验证试验,IPF队列仅24例。
  • 研究未报告长期疗效与安全性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cough can be a debilitating symptom of idiopathic pulmonary fibrosis (IPF) and is difficult to treat. PA101 is a novel formulation of sodium cromoglicate delivered via a high-efficiency eFlow nebuliser that achieves significantly higher drug deposition in the lung compared with the existing formulations. We aimed to test the efficacy and safety of inhaled PA101 in patients with IPF and chronic cough and, to explore the antitussive mechanism of PA101, patients with chronic idiopathic cough (CIC) were also studied. METHODS: This pilot, proof-of-concept study consisted of a randomised, double-blind, placebo-controlled trial in patients with IPF and chronic cough and a parallel study of similar design in patients with CIC. Participants with IPF and chronic cough recruited from seven centres in the UK and the Netherlands were randomly assigned (1:1, using a computer-generated randomisation schedule) by site staff to receive PA101 (40 mg) or matching placebo three times a day via oral inhalation for 2 weeks, followed by a 2 week washout, and then crossed over to the other arm. Study participants, investigators, study staff, and the sponsor were masked to group assignment until all participants had completed the study. The primary efficacy endpoint was change from baseline in objective daytime cough frequency (from 24 h acoustic recording, Leicester Cough Monitor). The primary efficacy analysis included all participants who received at least one dose of study drug and had at least one post-baseline efficacy measurement. Safety analysis included all those who took at least one dose of study drug. In the second cohort, participants with CIC were randomly assigned in a study across four centres with similar design and endpoints. The study was registered with ClinicalTrials.gov (NCT02412020) and the EU Clinical Trials Register (EudraCT Number 2014-004025-40) and both cohorts are closed to new participants. FINDINGS: Between Feb 13, 2015, and Feb 2, 2016, 24 participants with IPF were randomly assigned to treatment groups. 28 participants with CIC were enrolled during the same period and 27 received study treatment. In patients with IPF, PA101 reduced daytime cough frequency by 31·1% at day 14 compared with placebo; daytime cough frequency decreased from a mean 55 (SD 55) coughs per h at baseline to 39 (29) coughs per h at day 14 following treatment with PA101, versus 51 (37) coughs per h at baseline to 52 (40) cough per h following placebo treatment (ratio of least-squares [LS] means 0·67, 95% CI 0·48-0·94, p=0·0241). By contrast, no treatment benefit for PA101 was observed in the CIC cohort; mean reduction of daytime cough frequency at day 14 for PA101 adjusted for placebo was 6·2% (ratio of LS means 1·27, 0·78-2·06, p=0·31). PA101 was well tolerated in both cohorts. The incidence of adverse events was similar between PA101 and placebo treatments, most adverse events were mild in severity, and no severe adverse events or serious adverse events were reported. INTERPRETATION: This study suggests that the mechanism of cough in IPF might be disease specific. Inhaled PA101 could be a treatment option for chronic cough in patients with IPF and warrants further investigation. FUNDING: Patara Pharma.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Birring SS, Wijsenbeek MS, Agrawal S, et al. A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial. Lancet Respir Med. 2017. PMID: 28923239. doi:10.1016/S2213-2600(17)30310-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。